Received Mar 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | EY253 | — |
given a vaccine diluent of Shingrix without being reconstituted; given a vaccine diluent of Shingrix without being reconstituted; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 47-year-old male patient who received Herpes zoster (Shingrix) (batch number EY253, expiry date 16-JUL-2026) for prophylaxis. On 18-FEB-2025, the patient received Shingrix. On 18-FEB-2025, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: given a vaccine diluent of Shingrix without being reconstituted) and inappropriate dose of vaccine administered (Verbatim: given a vaccine diluent of Shingrix without being reconstituted). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 05-MAR-2025 Reporter had a patient who was given a vaccine diluent (Shingrix) without being reconstituted, which led to Inappropriate preparation of medication and Inappropriate dose of vaccine administered. Reporter was enquiring if he/she can revaccinate at any time and are there any potential concerns he should be notified if he only received diluent.